Medicare AdvantagePrior AuthMedium impact
MA08.159d, Mirvetuximab soravtansine-gynx (Elahere®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jun 15, 2026
We identified it
Jun 19, 2026
Summary
MA08.159d updates medical necessity criteria for Mirvetuximab soravtansine-gynx (Elahere®), a pharmacy benefit drug used in oncology. This recent policy change (1 month old) affects how claims for this medication are evaluated and approved under Medicare Advantage plans. Billing teams must ensure all prescriptions meet the new medical necessity requirements to avoid claim denials.
Action Required
By June 15, 2026: Billing and clinical teams must review the complete MA08.159d policy details at the provided URL to identify specific medical necessity criteria (e.g., diagnosis requirements, prior treatment history, clinical parameters). Update prior authorization submission templates and billing system edits to enforce these criteria. Providers must document all required medical necessity elements in patient records before submitting claims. Ensure pharmacy benefit coordinator and oncology providers are trained on new requirements. Claims submitted without documented medical necessity will be denied. Contact IBX or review the full policy text for specific criteria details, as the change summary provided does not contain the explicit medical necessity requirements.